title: Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
abstract: Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies.
authors.affiliation: Division of Infectious Diseases, Department of Pharmacy, Singapore General Hospital, Singapore. gpaklh@sgh.com.sg
authors.forename: Andrea L H
authors.initials: AL
authors.lastname: Kwa
authors.forename: ChinSiew
authors.initials: C
authors.lastname: Loh
authors.forename: Jenny G H
authors.initials: JG
authors.lastname: Low
authors.forename: Asok
authors.initials: A
authors.lastname: Kurup
authors.forename: Vincent H
authors.initials: VH
authors.lastname: Tam
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003091:Colistin / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D003091:Colistin